VITTIA
DEFESA E NUTRIÇÃO

EARNINGS RELEASE
3Q26



São Joaquim da Barra, November 11, 2026. Vittia S.A. (VITT3: BZ) ("**Vittia**" or "**Company**"), a Brazilian company specialized in biotechnology (biopesticides and inoculants) and special plant nutrition with solutions for several agricultural crops, announces its results for the third quarter of 2026 ("**3Q26**").

3Q26 Highlights

Adjusted net result of **R$ 39.2** million in 3Q26, reversing the loss recorded in the first half of 2026

Leverage at **1.41x** Adjusted EBITDA, maintaining a **balanced capital structure** and **financial flexibility**

Net revenue totaled **R$ 281.7** million in 3Q26 (**-13.3%** vs. 3Q25) and **R$ 517.7** million in 9M26 (**-7.9%** vs. 9M25)

Portfolio expansion with the launch of **4 new products** in 2026, alongside continued investment in RD&I, despite the challenging environment

Allocation of **R$ 44.7** million to shareholders in 9M26 beteween **share buybacks** and **interest on equity (JCP)**, reflecting the Company's confidence in the intrinsic value of the business and its long-term prospects

Our Business

We operate in three product divisions, which are our reportable segments: (i) Soil Fertilizers; (ii) Foliar Fertilizers and Industrial Products; and (iii) Biological and Natural Solutions. These divisions have centralized management under the same corporate division, including the Board of Directors and Advisory Committees, Executive Board, Control and Operating Systems, and Technology and People, among others. We have specialized and capable teams to provide high-quality and unique products to continuously meet market demand and, with a focus on superior productivity and financial performance under the ESG matrix.

Message from Management

The third quarter of 2026, a critical period for the start of the 2026/27 summer crop season, continued to be characterized by a challenging environment for Brazilian agribusiness. Farmers remained under pressure from tighter margins, high financing costs, and more selective credit availability, amid persistently high levels of indebtedness across the sector. In addition, uncertainties surrounding the electoral period and weather conditions for the 2026/27 crop season heightened caution among farmers and distribution channels, contributing to more selective purchasing decisions for agricultural inputs and more conservative inventory and working capital management.

Despite this adverse environment, Vittia delivered a significant recovery in profitability throughout the year, reporting adjusted net income of R$ 39.2 million in 3Q26, with a margin of 13.9%, fully offsetting the adjusted net loss of R$ 23.3 million accumulated in the first half of 2026. Reflecting the more restrictive demand environment, net revenue reached R$ 281.7 million in 3Q26, a decrease of 13.3% compared to the same period of the previous year, totaling R$ 517.7 million in the first nine months of 2026, a 7.9% decline compared to 9M25. Adjusted EBITDA reached R$ 68.3 million in the quarter, with a margin of 24.2%, while totaling R$ 50.8 million in 9M26, with a margin of 9.8%.

Although year-to-date results still reflect the effects of the adverse cycle faced by the agribusiness sector, Vittia has demonstrated operational and financial resilience throughout 2026. During the quarter, the Company maintained the quality of its results, achieving a gross margin of 33.1%, an increase of 0.9 percentage points compared to 3Q25, while sustaining a solid level of operating profitability. We remain focused on financial discipline, prudent resource management, and the continuous improvement of our operating structure. Cost rationalization and control initiatives, implemented since late 2023, remain among our priorities. In the first nine months of 2026, our adjusted selling, general and administrative expenses (SG&A) increased by only 2.5% in nominal terms, below inflation for the period, thus representing a reduction in real terms. This performance reinforces the effectiveness of the efficiency measures adopted by the Company and our ability to adapt our cost structure to the current business environment.

We have maintained our commitment to innovation and the development of solutions that contribute to the productivity and profitability of rural producers. Throughout 2026, we expanded our portfolio with four new product launches: Guardium WP, a biological insecticide that combines two complementary agents; RizoForte, a solution specifically designed for nematode management; AeronN, a foliar-applied technology that supports biological nitrogen fixation processes; and Fillus, developed to provide more balanced and efficient plant nutrition. These launches strengthen our presence across various aspects of agricultural management, incorporating technological advancements such as the VIT CORE™ platform, and reflect our continued investment in Research, Development, and Innovation, one of Vittia's strategic pillars.

Maintaining these investments, even during a period of greater restrictions across the sector, reflects our long-term vision and confidence in the growth potential of the biological crop protection and specialty plant nutrition markets. We believe that our diversified portfolio, combined with our innovation capabilities and close relationships with farmers and distribution channels, represents an important competitive advantage, strengthening our market position and expanding growth opportunities as market conditions become more favorable.

At the same time, we remained committed to our financial discipline principles, maintaining strict credit granting criteria and working capital control. The Company ended the period with leverage of only 1.4x adjusted EBITDA, preserving a balanced capital structure and the financial flexibility needed to navigate the current cycle, continue investing in strategic priorities, and maintain a disciplined approach to capital allocation.

This financial strength enabled us to combine business investments with capital returns to shareholders, even amid an adverse industry environment. In 9M26, we allocated R$ 44.7 million to shareholders, comprising R$ 19.3 million through the share buyback program and R$ 25.5 million in Interest on Equity (IoE). Under current market conditions, we believe that share repurchases represent an attractive capital allocation alternative and reflect Management's confidence in the Company's long-term value. Accordingly, we continue

to balance low leverage, investment capacity, and shareholder returns, while preserving financial flexibility to capture growth opportunities as market conditions improve.

Looking ahead to the final quarter of 2026 and the remainder of the 2026/27 crop season, we remain attentive to developments in credit conditions, agricultural commodity prices, weather patterns, and the pace of agricultural input sales. We remain confident in the structural fundamentals of Brazilian agribusiness and the growth potential of the biological technologies and specialty plant nutrition markets. We will continue investing in these segments, maintaining financial discipline, and strengthening our competitive position, with a focus on sustainable value creation and capturing the opportunities expected to emerge as market conditions normalize.

Economic and Financial Performance

In thousands of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Net revenue	**281,731**	**324,954**	**(13.3%)**	**517,693**	**561,834**	**(7.9%)**
Cost of goods sold	(188,492)	(220,197)	(14.4%)	(371,604)	(400,904)	(7.3%)
Gross profit	**93,239**	**104,756**	**(11.0%)**	**146,089**	**160,929**	**(9.2%)**
Gross margin	33.1%	32.2%	0.9 p.p.	28.2%	28.6%	-0.4 p.p.
Operating expenses (i)	**(48,896)**	**(55,546)**	**(12.0%)**	**(139,845)**	**(144,404)**	**(3.2%)**
Adjusted EBITDA	**68,254**	**83,503**	**(18.3%)**	**50,835**	**69,584**	**(26.9%)**
Adjusted EBITDA margin	24.2%	25.7%	-1.5 p.p	9.8%	12.4%	-2.6 p.p
Net financial result	**174**	**(743)**	**N/A**	**2,000**	**(2,047)**	**N/A**
Income tax and social contribution	(10,472)	(9,033)	15.9%	1,404	1,814	(22.6%)
Net result	**34,045**	**39,434**	**(13.7%)**	**9,648**	**16,292**	**(40.8%)**
Net margin	12.1%	12.1%	0.0 p.p.	1.9%	2.9%	-1.0 p.p.
Adjusted Net result (ii)	**39,163**	**51,297**	**(23.7%)**	**15,841**	**28,155**	**(43.7%)**
Net margin	13.9%	15.8%	-1.9 p.p.	3.1%	5.0%	-1.9 p.p.
Investments (fixed and intangible assets)	**7,227**	**9,552**	**(24.3%)**	**22,567**	**24,522**	**(8.0%)**

(i) Adjusted net income excludes impacts related to the decommissioning of the Vittia Organo S.A. manufacturing facility located in Patos de Minas, Minas Gerais (MG); the non-recurring recovery of taxes; and financial advisory expenses incurred in securing financing from FINEP. These adjustments are presented net of their respective tax effects.

Operating income


Net operating income by segment

In thousands of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Soil fertilizers	74,281	106,275	(30.1%)	164,317	184,567	(11.0%)
Foliar fertilizers and industrial products	104,265	109,844	(5.1%)	172,326	194,786	(11.5%)
Biological and natural solutions	103,185	108,835	(5.2%)	181,050	182,481	(0.8%)
Net revenue	**281,731**	**324,954**	**(13.3%)**	**517,693**	**561,834**	**(7.9%)**

Geographic breakdown

Vittia is present throughout Brazil and abroad, with revenue broken down as follows:

Breakdown of net revenue per region (R$ million)



Gross profit and gross margin

In thousands of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Soil fertilizers	**8,674**	**10,941**	**(20.7%)**	**11,153**	**13.612**	**(18.1%)**
Gross margin	11.7%	10.3%	1.4 p.p.	6.8%	7.4%	-0.6 p.p.
Foliar fertilizers and industrial products	**27,379**	**27,086**	**1.1%**	**39,717**	**38,856**	**2.2%**
Gross margin	26.3%	24.7%	1.6 p.p.	23.0%	19.9%	3.1 p.p.
Biological and natural solutions	**57,186**	**66,729**	**(14.3%)**	**95,219**	**108,461**	**(12.2%)**
Gross margin	55.4%	61.3%	-5.9 p.p.	52.6%	59.4%	-6.8 p.p.
Gross profit	**93,239**	**104,756**	**(11.0%)**	**146,089**	**160,929**	**(9.2%)**
Gross margin	**33.1%**	**32.2%**	**0.9 p.p.**	**28.2%**	**28.6%**	**-0.4 p.p.**

Selling, general and administrative expenses (SG&A)

In thousands of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Selling expenses	(18,659)	(21,282)	(12.3%)	(51,214)	(54,234)	(5.6%)
Provision for expected credit losses	(5,091)	(1,172)	334.4%	(5,027)	(390)	1189.0 %
General and administrative expenses	(22,763)	(19,131)	19.0%	(83,483)	(76,084)	9.7%
Other operating income (expenses)	(2,383)	(13,961)	(82.9%)	(121)	(13,695)	(99.1%)

Total SG&A expenses	**(48,896)**	**(55,546)**	**(12.0%)**	**(139,845)**	**(144,404)**	**(3.2%)**
Net revenue (%)	*17.4%*	*17.1%*	*0.3 p.p.*	*27.0%*	*25.7%*	*1.3 p.p.*
(+) Late recovery of taxes (i)	733	-	N/A	2,360	-	N/A
(+) Advisory fees for FINEP financing arrangement (ii)	2,347	-	N/A	2,347	-	N/A
(+) Write-off of fair value of property, plant and equipment – Vittia Organo (iii)	3,086	-	N/A	3,086	-	N/A
(+) Unit demobilization (iv)	-	15,568	N/A	-	15,568	N/A
Total adjusted SG&A	**(42,730)**	**(39,978)**	**6.9%**	**(132,052)**	**(128,836)**	**2.5%**
Net revenue (%)	*15.2%*	*12.3%*	*2.9 p.p.*	*25.5%*	*22.9%*	*2.6 p.p.*

(i) In 9M26, the company made a payment of fees resulting from the late recovery of taxes carried out in 2025. At that time, the company reviewed the tax records from April 2021 to March 2025 and identified late tax credits of R$ 24,296 thousand relating to previous years.

(ii) In 3Q26, the Company made payments for financial advisory expenses incurred during the process of obtaining financing from FINEP.

(iii) In 3Q26, the Company wrote off the fair value increment (step-up) attributed to property, plant, and equipment, which had been recognized at the time of the company's acquisition.


(iv) In September 2025, the Company completed the decommissioning of a manufacturing facility belonging to Vittia Organo S.A. located in Patos de Minas, Minas Gerais (MG). This action was in line with the strategic plan to optimize the Company's production structure and consolidate operations at the facility located in Serrana, São Paulo (SP). The decommissioning did not compromise the Company's overall production capacity, as production was redistributed among its other manufacturing units. The total accounting impact related to this decommissioning amounted to R$ 15.6 million and was recognized in its entirety in the results for the period.

SG&A totaled R$ 132.1 million in 9m26, representing 25.5% of net revenue, a 2.6 p.p. increase compared to 9M25. The Company remains focused on its operational efficiency strategy, preserving its commercial capacity and sustaining its growth.


Adjusted EBITDA and Adjusted EBITDA Margin

The Company's adjusted EBITDA (excluding the adjustment to the present value of accounts receivable and non-recurring events) was R$ 50.8 million in 9M26, with an adjusted EBITDA margin of 9.8%, mainly due to the reduction in gross profit.

Adjusted EBITDA Performance (R$ million)



Adjusted EBITDA margin performance



(i) SGA = General, administrative, other and non-recurring expenses
(ii) AFDA = Allowance for Doubtful Accounts
(iii) D&A = Depreciation and amortization / PVA = Present value adjustment

Reconciliation of net income and adjusted EBITDA

In thousands of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Net result	34,045	39,434	(13.7%)	9,648	16,292	(40.8%)
(+) Income tax and social contribution	10,472	9,033	15.9%	(1,404)	(1,814)	(22.6%)
(+) Net financial income (loss)	(174)	743	N/A	(2,000)	2,047	N/A
(+) Depreciation and amortization	6,278	6,644	(5.5%)	18,316	18,971	(3.5%)
EBITDA (i)	**50,621**	**55,854**	**(9.4%)**	**24,560**	**35,497**	**(30.8%)**
EBITDA Margin (i)	*18.0%*	*17.2%*	*0.8 p.p.*	*4.7%*	*6.3%*	*-1.6 p.p.*
(+) Present value adjustment – PVA	11,467	12,081	(5.1%)	18,482	18,519	(0.2%)
(+) Late recovery of taxes (iii)	733	-	N/A	2,360	-	N/A
(+) Advisory fees for FINEP financing arrangement (ii)	2,347	-	N/A	2,347	-	N/A

(+) Write-off of fair value of property, plant and equipment – Vittia Organo (iii)	3,086	-	N/A	3,086	-	N/A
(+) Unit demobilization (iv)	-	15,568	N/A	-	15,568	N/A
Adjusted EBITDA (ii)	**68,254**	**83,503**	**(18.3%)**	**50,835**	**69,584**	**(26.9%)**
Adjusted EBITDA margin (i)	*24.2%*	*25.7%*	*-1.5 p.p*	*9.8%*	*12.4%*	*-2.6 p.p*

(i): EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-accounting measure disclosed by the Company under CMV Instruction 527 of October 4, 2012 ("CMV Instruction 527"), reconciled with its financial statements, and consists of net income plus net financial result, income tax and social contribution expenses, and depreciation and amortization expenses and costs. The EBITDA margin is calculated by dividing EBITDA by the net operating income. Adjusted EBITDA is a non-GAAP financial measure under the accounting practices adopted in Brazil and accepted under IFRS. Adjusted EBITDA is calculated by taking EBITDA and adding back adjustments for the present value of accounts receivable, as well as other non-recurring events. The adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net operating revenue.

(ii) In 9M26, the company reviewed its tax records from April 2021 to March 2025 and identified overdue tax credits of R$ 24,296 thousand relating to previous fiscal years.

(iii) In 3Q26, the Company made payments for financial advisory expenses incurred during the process of obtaining financing from FINEP.

(iv): In 3Q26, the Company wrote off the fair value increment (step-up) attributed to property, plant, and equipment, which had been recognized at the time of the company's acquisition.

(v): In September 2025, the Company completed the decommissioning of a manufacturing facility belonging to Vittia Organo S.A. located in Patos de Minas, Minas Gerais (MG). This action was in line with the strategic plan to optimize the Company's production structure and consolidate operations at the facility located in Serrana, São Paulo (SP). The decommissioning did not compromise the Company's overall production capacity, as production was redistributed among its other manufacturing units. The total accounting impact related to this decommissioning amounted to R$ 15.6 million and was recognized in its entirety in the results for the period.

Financial result

In thousands of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Interest income and discounts	583	592	(1.5%)	3,908	1,829	113.7%
Present value adjustment (i)	5,650	5,543	1.9%	19,129	18,066	5.9%
Income from financial investments	1,347	1,230	9.5%	4,630	3,263	41.9%
Interest expenses	(3,051)	(6,662)	(54.2%)	(20,768)	(17,130)	21.2%
Discounts granted	(372)	(116)	220.7%	(1,545)	(1,321)	17.0%
Interest on right of use	(568)	(580)	(2.1%)	(1,781)	(2,109)	(15.6%)
Other financial expenses and IOF (Tax on Financial Operations)	(1,036)	(912)	13.6%	(1,193)	(1,188)	0.4%
Exchange variation, net (ii)	(1,290)	(235)	448.9%	(540)	8,504	N/A
Gains (losses) with derivatives (ii)	(1,090)	397	N/A	160	(11,961)	N/A
Net financial result	**174**	**(743)**	**N/A**	**2,000**	**(2,047)**	**N/A**

(i) The Present Value Adjustment (PVA), which includes our sales realized in the "Crop Period". In this procedure, the "Accounts Receivable" resulting from such sales are adjusted to their present value through discounts that consider pre-fixed embedded interest. To bring the "Accounts Receivable" to present value we use the average weighted funding cost. This practice has the following impact on our balance sheet and results: in the first moment, the PVA is deducted from our "Accounts Receivable" through an account that reduces the balance sheet, while gross revenue is also deducted at the same amount. With time, the amount deducted is accrued in the financial result under interest gains, reducing the value of the account that reduces the "Accounts Receivable". The monthly accrual is based on the rate used for the discount at the initial moment. Accordingly, upon payment, the value of "Accounts Receivable" is offset by fully debiting the cash account, and the total gross revenue arising from the sale in installments will be partially accrued as operating income upon delivery of the good and partially accrued every month as financial revenue until the payment is made

(ii) To protect itself against risks from exchange rate variations, the Company uses derivative hedging instruments, mainly foreign exchange swaps and NDFs (non deliverable forwards). NDFs are generally used to manage currency exposure on balance sheets, avoiding or minimizing the mismatch on accounts receivable, operating liabilities, and accounts payable that are denominated in dollars. Swaps are usually contracted through


operations known as "4131 swaps". In these operations, the Company contracts a debt instrument in foreign currency (Dollar or Euro) with a financial institution, while contracting, at the same time, a swap operation, exchanging this obligation in foreign currency (long end for the Company) for yields based on the variation of Interbank Deposit Certificates – CDI, plus a spread (short end for the Company). These operations are carried out with the same counterparty and with the same amounts and maturity dates. Swaps are classified as fair value derivatives and their results are accounted for as gains (losses) on derivatives. Foreign currency debt is classified under loans and financing, with the result from the exchange variation and interest accounted for as financial expenses.

The net financial result for 3Q26 was R$ 0.2 million (a reversal of the negative result of R$ 0.7 million in 3Q25). In the 9M26, the result was a positive R$ 2.0 million (a reversal of the negative result of R$ 2.0 million in 9M25). The change in the result for the period is primarily due to a higher volume of interest income recognized, as well as an increase in returns on financial investments compared to the same period of the previous year.

Cash flow management and indebtedness

Cash flow management

Cash flow (R$ million)



In Thousand of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Cash Generation	**(40,666)**	**12,422**	**N/A**	**17,240**	**21,556**	**(20.0%)**
Operating activities	(42,383)	34,012	N/A	60,202	106,087	(43.3%)
Investments	(7,474)	(9,904)	(24.5%)	(21,794)	(23,526)	(7.4%)
Financing	9,190	(11,686)	N/A	(21,169)	(61,005)	(65.3%)
Cash and cash equivalents at beginning of period	**105,868**	**63,607**	**66.4%**	**47,963**	**54,473**	**(12.0%)**
Cash and cash equivalents at end of period	**65,203**	**76,029**	**(14.2%)**	**65,203**	**76,029**	**(14.2%)**

The cash variation in 9M26 was positive by R$ 17.2 million due to the amortization of financing, which reached R$ 21.2 million (-65.3% vs. 9M25) and investments, which totaled R$ 21.8 million (-7.4% vs. 9M25), offset by operating activities, which totaled R$ 60.2 million (-43.3% vs. 9M25).

Indebtedness

The Company's gross debt reached R$ 201.2 million in 9M26 (+4.6% vs. 9M25), while net debt registered R$ 136.0 million (+17.0% vs. 9M25). The net debt/EBITDA ratio came to 1.41x.

In thousands of R$, except %	9M26	9M25	Chg. %	2025	Chg. %
Loans and financing (current)	122,821	142,741	(14.0%)	124,930	(1.7%)
Loans and financing (non-current)	78,381	49,539	58.2%	48,627	61.2%
Gross debt	**201,202**	**192,280**	**4.6%**	**173,557**	**15.9%**
(-) Cash and cash equivalents	(65,203)	(76,029)	(14.2%)	(47,963)	35.9%
Net debt (i)	**135,999**	**116,251**	**17.0%**	**125,594**	**8.3%**
LTM Adjusted EBITDA	*96,475*	*130,922*	*(26.3%)*	*115,223*	*(16.3%)*
Net Debt/LTM EBITDA	**1.41x**	**0.89x**	**0.52x**	**1.09x**	**0.32x**

CAPEX and Research, Development and Innovation

Investments in CAPEX reached R$ 22.6 million in 9M26 (-8.0% vs. 9M25). These CAPEX investments are primarily focused on operational improvements that can generate productivity gains and cost reductions, without focusing on large-scale projects. The CAPEX strategy seeks to adapt to the current moment of increased conservatism in agribusiness and rising interest rates in the country, seeking the efficient allocation of capital. The main investments planned for 2026 are:

Biologicals Plant:

We continued the implementation of a new, modern filling cell for the line of formulated products, with the objective of meeting new market demands and providing greater operational flexibility for the incorporation of new SKUs into the portfolio. An investment of R$ 2.0 million was made in this project during the third quarter of 2026 3Q26. In 9M26, the total investment in the project reached R$ 3.3 million.

Inoculants Plant:

With a view toward operational improvements and modernization, we expanded the fermentation area to support the entire inoculants products line, resulting in an increase in production capacity of 1,920,000 doses per month. In 3Q26, R$ 1.9 million was invested, bringing the total investment for the first nine months of 2026 9M26 to R$ 4.7 million. Following this expansion, the facility now possesses the infrastructure required to operate at 100% of its designed capacity.

R&D Investments

The Company generates value through integrated teams, combining knowledge and experience from the areas of R&DI, Market Development and Regulatory Affairs. At the end of 3Q26, we had 53 R&DI professionals, 37 of whom were exclusively dedicated to this area.

In 9M26, the Company invested R$ 18.5 million in research and development, which represents a 8.7% reduction compared to the same period of the previous year and corresponds to 3.6% of the Company's net revenue, remaining stable relative to 9M25. It is worth noting the seasonal nature of CAPEX investments, which does not indicate a reduction in the Company's R&D investments.

Research and Development Investments

In thousand of R$	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Biological products	4,616	5,361	(13.9%)	14,048	15,395	(8.7%)
Fertilizers	1,400	1,591	(12.0%)	4,485	4,901	(8.5%)
Total	**6,016**	**6,953**	**(13.5%)**	**18,533**	**20,296**	**(8.7%)**
Capex	290	538	(46.1%)	675	703	(3.9%)
Opex	5,726	6,415	(10.7%)	17,858	19,593	(8.9%)
Net revenue (%)	2.1%	2.1%	0.0 p.p.	3.6%	3.6%	0.0 p.p.

Key developments

With deep roots in research and innovation in the field, Vittia has become a national benchmark in biological crop protection and plant nutrition. Our commitment is to boost crop performance through sustainable, effective, and technological solutions, supported by ethics, knowledge, and experience.

We offer a complete and integrated portfolio that strengthens productivity and profitability while also contributing to the development of increasingly sustainable agriculture. During the quarter, the Company obtained 5 new recommendations for biological use/targets and 5 new Temporary Special Registrations.

During the period, Vittia also expanded its portfolio with four new product launches:

- **Guardium WP:** a biological insecticide and the Company's first solution to combine two complementary biological agents. It incorporates VIT CORE™ technology, which provides formulation enhancements designed to improve the protection, stability, and field performance of biological agents;
- **RizoForte:** a solution designed to manage nematodes at different stages of their life cycle, particularly eggs and females. It works in a complementary manner to No-Nema, expanding management options;
- **Aeron-N:** a new foliar application technology that supports biological nitrogen fixation processes and combines bioactive compounds, including biological nanoparticles, associated with plant vigor and physiological efficiency. It also incorporates VIT CORE™ technology; and
- **Fillus:** a solution that combines essential macro and micronutrients to promote more balanced and efficient plant nutrition.

These launches strengthen the Company's presence across biological crop protection, biostimulation, and plant nutrition, and reflect its strategy of continuously investing in Research, Development, and Innovation to provide farmers with enhanced technology, efficiency, and productivity.

Human Resources

We ended 3Q26 with 1,069 employees, compared to 1,073 in the previous quarter (-0.4% vs. 2Q26) and 1,120 in the same period of the previous year (-4.6% vs. 3Q25). All our employees, including those under temporary employment contracts, are directly hired by the Company under the Brazilian Consolidation of Labor Laws (CLT).

The Company maintains a close relationship with the unions that represent its employees. Collective agreements and conventions, as well as those negotiated directly, have a usual duration of 12 months. Vittia

also complies with applicable labor laws and conditions established in collective bargaining agreements signed with labor unions, applying them equally to unionized and non-unionized employees.

Capital Markets

The shares of Vittia S.A. (B3: VITT3) have been traded since the IPO, on September 1, 2021, in the Novo Mercado segment of B3, the highest Corporate Governance level in the Brazilian stock market. The Company is also included in the IGC (Special Corporate Governance Stock Index), IGC-NM (Novo Mercado Corporate Governance Equity Index), and ITAG (Special Tag-Along Stock Index) indexes.

Share capital: Vittia's share capital was constituted, on 09/30/2026, by 157.6 million common shares (ON), of which 66.9% belonged to controlling shareholders, 2.6% to the Company's management, 29.4% were in free circulation on the market ("free float") and 1.1% were shares held in treasury.

Market cap: At the end of the quarter, VITT3 share was priced at R$ 3.07, representing a market cap of R$ 483.8 million, compared to R$ 513.7 million at the end of the previous quarter, a decrease of 5.8% or R$ 29.9 million.

Free-float Breakdown: At the end of 3Q26, the free float was distributed as follows: individual investors held 16.2% (vs. 15.5% in 2Q26), local institutional investors held 82.5% (vs. 82.2% in 2Q26), and foreign investors held 1.3% (vs. 2.3% in 2Q26).

Number of shareholders: At the end of the quarter, the Company had 4.3 thousand shareholders, compared to 4.4 thousand at the end of 2Q26, a decrease of 4.4%.

Average Daily Trading Volume ("ADTV"): The average daily trading volume was R$ 0.6 million in 3Q26, compared to R$ 1.0 million in the previous quarter, a decrease of R$ 0.4 million or 35.9%.

Dividend distribution: By the end of 3Q26, the Company had paid R$ 25.5 million in dividends, as JCP, paid on 01/06/2026 and 05/11/2026.

In the RCA held on July 14, 2025, the declaration of distribution of JCP calculated in the period from January to July 2025 was approved, in the gross amount of R$ 20.8 million (R$ 0.14040135117 per share) based on the shareholding position of July 18, 2025. The first installment, in the amount of R$ 7.0 million (R$ 0.04731352488 per share), was paid on August 13, 2025 and the second installment, in the amount of R$ 6.0 million (R$ 0.04055444989 per share) was paid on 09/03/2025, and the third installment, in the amount of R$ 7.8 million (R$ 0.05253337640) was paid on January 6, 2026.

At a Board of Directors' Meeting held on October 29, 2025, the declaration of distribution of Interest on Equity accrued in the period from August to October 2025 was approved, in the gross amount of R$ 9.5 million (R$ 0.06474713761 per share) based on the shareholding position of November 3, 2025. The first installment, in the amount of R$ 4.7 million (R$ 0.03214434305 per share), was paid on January 6, 2026; the second installment, in the amount of R$ 4.8 million (R$ 0.03260279456 per share) was paid on May 11, 2026.

Furthermore, at a meeting of the Board of Directors held on December 17, 2025, the distribution of Interest on Equity ("JCP") was approved, totaling R$ 6.6 million (R$ 0.04514632207 per share), based on the shareholding position as of November 3, 2025, with a payment date of May 11, 2026. Additionally, at a meeting of the Board of Directors held on December 30, 2025, the distribution of Interest on Equity ("JCP"), accrued during the period from 1996 to 2005, was approved, in the gross amount of R$ 4.7 million (R$ 0.03225465391 per share), also to be paid on May 11, 2026.

At a meeting of the Board of Directors held on September 22, 2026, the distribution of interest on equity (JCP), accrued during the period from January to April 2026, was approved in the total gross amount of R$ 13.3 million (R$ 0.08504375896 per share), based on the shareholding position as of September 28, 2026, with payment to be made on October 21, 2026.

Share buyback program: On June 9, 2026, the Company announced that its Board of Directors had approved the 6th Share Buyback Program, covering the acquisition of up to 4,500,000 common shares, representing approximately 9.4% of the Company's outstanding shares at that time, with a maximum term of 12 months.

In 9M26, the Company repurchased shares totaling R$ 19.3 million, taking into account shares repurchased under both the 5th and 6th Share Buyback Programs. As of the end of October 2026, the Company held 2,155,142 shares in treasury.

Furthermore, also on June 9, 2026, the Company announced the cancellation of 4,455,436 common shares held in treasury—which had been acquired under the Company's 5th share buyback program—without a reduction in share capital. This cancellation was carried out specifically for the purposes of Articles 9 and 10 of CVM Resolution No. 77, dated March 29, 2022 ("CVM Resolution No. 77/22"), and was charged against available profit reserve balances, excluding the reserve balances specified in Article 8, Paragraph 1, Item I of CVM Resolution No. 77/22.

Increase in Share Capital with Share Bonus: At a Board of Directors' Meeting (RCA) held on December 30, 2025, Vittia S.A. approved an increase in its share capital through the capitalization of R$ 137.1 million recorded in profit reserves in the balance sheet as of December 31, 2024, with the resulting bonus share distribution to shareholders. As a result of this transaction, 14,731,402 new common shares were issued and granted free of charge at a ratio of 10% (10 new shares for every 100 shares held), based on the shareholder position as of April 9, 2026. The bonus shares were credited to shareholders on April 13, 2026 and will carry the same rights as the existing shares, including full entitlement to dividends and/or interest on shareholders' equity declared with a record date after April 14, 2026. As a result, and considering the cancellation of shares mentioned in the section above, the Company's share capital is now divided into 157,589,984 shares.

Basic Financial Statements

Income Statement for the Year – 3Q26 vs. 3Q25 and 9M26 vs. 9M25

Income Statement (R$ thousand)	3Q26	3Q25	Chg. %	9M26	9M25	Chg. %
Net revenue	**281,731**	**324,954**	**(13.3%)**	**517,693**	**561,834**	**(7.9%)**
Sales costs	(188,492)	(220,197)	(14.4%)	(371,604)	(400,904)	(7.3%)
Gross profit	**93,239**	**104,756**	**(11.0%)**	**146,089**	**160,929**	**(9.2%)**
Gross margin	33.1%	32.2%	0.9 p.p.	28.2%	28.6%	-0.4 p.p.
Selling expenses	(18,659)	(21,282)	(12.3%)	(51,214)	(54,234)	(5.6%)
Provision for expected credit losses	(5,091)	(1,172)	334.4%	(5,027)	(390)	1189.0 %
General and administrative expenses	(22,763)	(19,131)	19.0%	(83,483)	(76,084)	9.7%
Other net operating income (expenses)	(2,383)	(13,961)	(82.9%)	(121)	(13,695)	(99.1%)
SG&A expenses	**(48,896)**	**(55,546)**	**(12.0%)**	**(139,845)**	**(144,404)**	**(3.2%)**
Operating profit	**44,343**	**49,210**	**(9.9%)**	**6,244**	**16,526**	**(62.2%)**
Financial income	8,542	8,213	4.0%	30,599	33,910	(9.8%)
Financial expenses	(8,368)	(8,956)	(6.6%)	(28,599)	(35,957)	(20.5%)
Financial result	**174**	**(743)**	**N/A**	**2,000**	**(2,047)**	**N/A**
Profit (loss) before income tax and social contribution	**44,517**	**48,467**	**(8.2%)**	**8,244**	**14,478**	**(43.1%)**
Current and Deferred Income Tax and Social Contribution	(10,472)	(9,033)	15.9%	1,404	1,814	(22.6%)
Result for the period	**34,045**	**39,434**	**(13.7%)**	**9,648**	**16,292**	**(40.8%)**
Net margin	12.1%	12.1%	0.0 p.p.	1.9%	2.9%	-1.0 p.p.

Cash Flow Statements – 9M26 vs. 9M25

In thousands of R$, except %	9M26	9M25
Cash Flow from Operating Activities		
Result for the period	**9,648**	**16.292**
Adjustments for:		
Depreciation and amortization	18,316	18,971
Residual cost of sold/written-off fixed assets	1,006	8,202
Current taxes	968	1,181
Deferred taxes	(2,372)	(2,995)
Provision for bônus	970	-
Provision for commissions	4,204	9,674
Write-off of fair value increment – Vittia Organo S.A.	3,086	-
Interest and monetary variations on loans and financing	19,134	20,461
Interest on lease liabilities	1,781	2,325
Present value adjustment variation	(647)	249
Provision for doubtful accounts	5,027	390
Fair value of derivate financial instruments	(160)	11,960
Provision for contingencies	32	78
Write-off of right-of-use asset and lease liability	213	-
Exchange Variation	2,785	(6,466)
Change in working capital		
Increase (decrease) in trade receivables	61,122	64,256
Increase (decrease) in inventories	(65,778)	(42,836)
Increase (decrease) in taxes recoverable	12,746	5,554
Increase (decrease) in other receivables	145	2,589
Increase (decrease) in suppliers	17,312	12,594
Increase (decrease) in payroll and social security charges	1,789	822
Increase (decrease) in taxes and contributions payable	(1,498)	(36)
Increase (decrease) in advances from customers	5,198	9,924
Increase (decrease) in other accounts payable	(6,224)	(5,182)
Cash generated by Operations	**88,803**	**128,007**
Income tax and social contribution paid	(793)	(1,118)
Interest paid on lease liabilities	(1,781)	(2,325)
Interest paid on loans and financing	(26,027)	(18,477)
Net cash from operating activities	**60,202**	**106,087**

Cash Flow Statements – 9M26 vs. 9M25 *(continued)*

Cash flows from investing activities		
Receivables from the sale of fixed assets	773	1,167
Acquisition of fixed assets	(22,291)	(24,593)
Increase in intangible assets	(276)	(100)
Net cash flow used in investing activities	**(21,794)**	**(23,526)**
Cash flows from financing activities		
Loans and financing raised	214,489	118,000
Payment of lease liabilities	(5,471)	(5,223)
Payment of loans and financing	(182,735)	(120,735)
Realized derivative financial instruments	(2,703)	(5,838)
Acquisition of treasury shares	(19,268)	(13,420)
Dividends paid	(25,481)	(33,789)
Net cash flows generated by financing activities	**(21,169)**	**(61,005)**
Increase (decrease) in cash and cash equivalents, net	**17,240**	**21,556**
Cash and cash equivalents at the beginning of the period	**47,963**	**54,473**
Cash and cash equivalents at the end of the period	**65,203**	**76,029**

Balance Sheet as of September 30, 2026 and December 31, 2025

In thousands of R$, except %	9M26	2025
Assets		
Current assets	578,667	575,949
Cash and cash equivalents	65,203	47,963
Derivative Financial Instruments – Assets	104	-
Trade receivables	261,835	327,881
Inventories	223,568	157,790
Taxes recoverable	21,839	33,625
Current tax asset	2,671	5,026
Other receivables	3,447	3,664
Non-current assets	367,514	360,040
Non-current receivables	**26,236**	**20,800**
Trade receivables	2,537	1,993
Taxes recoverable	3,713	3,624
Deferred tax asset	14,365	13,732
Current tax asset	4,098	-
Judicial deposits	1,523	1,451
Permanent	**341,278**	**339,240**
Investments	254	255
Fixed assets	308,603	302,120
Right of use	18,376	23,096
Intangible assets	14,045	13,769
Total assets	946,181	935,989
Liabilities and equity		
Current liabilities	224,668	217,187
Suppliers	33,555	14,197
Loans and financing	122,821	124,930
Derivative Financial Instruments	141	2,784
Payroll and social security charges	23,847	20,753
Taxes and contributions payable	3,794	3,540
Current tax liabilities	651	781
Advances from customers	11,880	6,682
Dividends to distribute and interest on equity	11,500	25,481
Lease liability	6,231	6,956
Other accounts payable	10,248	11,083
Non-current liabilities	98,841	74,429
Loans and financing	78,381	48,627
Provision for risks	767	735
Deferred tax liability	4,304	6,043
Lease liability	15,389	19,024
Total equity attributable to controlling shareholders	622,504	644,605
Non-controlling interests	168	(232)
Total equity	622,672	644,373
Total liabilities	323,509	291,616
Total liabilities and equity	946,181	935,989

Investor Relations

Alexandre Del Nero Frizzo – CFO and IRO

Laís Nunes – IR Specialist

ri@vittia.com.br

ri.vittia.com.br